Lypo-C CBD from the Liposomal Supplement Brand 'Lypo-C' to Launch Pre-sales for Medical Institutions on June 9th (Mon)

SPIC Corporation (Headquarters: Kamakura, Kanagawa; President: Takayuki Shibata), which supports personal health under the mission of 'Creating the Future of Health,' will begin pre-sales of its new product, 'Lypo-C CBD,' for medical institutions on June 9, 2025. CBD has been confirmed safe by international organizations such as the WHO, and with the amendment of the Cannabis Control Act in Japan in December 2024, a legal framework has been established. This marks the beginning of an era where CBD is correctly understood and utilized. SPIC proposes 'Lypo-C CBD,' a medical-grade liposomal supplement focused on absorption and safety. By applying proprietary Lypo-Capsule technology, the CBD is encapsulated in fine liposomes to maximize absorption. It uses broad-spectrum CBD, which contains no THC (<1ppm) and allows multiple cannabinoid components to work gently. Through 'Lypo-C CBD,' we aim to contribute to people's health by delivering 'certain results' and 'correct value,' while pioneering the future of CBD.